ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer

Oliver Sartor, MD
Published: Monday, Aug 28, 2017



Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer (mCRPC) and the potential for combinations with this agent.

In this comparative analysis, African Americans with mCRPC receiving sipuleucel-T had a higher median overall survival when compared with Caucasian patients.

Regarding combinations with this agent, there are only hypothesized studies. There is still more to learn with sipuleucel-T, Sartor says.

   


Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer (mCRPC) and the potential for combinations with this agent.

In this comparative analysis, African Americans with mCRPC receiving sipuleucel-T had a higher median overall survival when compared with Caucasian patients.

Regarding combinations with this agent, there are only hypothesized studies. There is still more to learn with sipuleucel-T, Sartor says.

   



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x